DS
TTPH

DRW Securities’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

DRW Securities’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-950
Closed -$207K – 183
2014
Q1 		$207K Buy
+950
New +$265K 0.02% 108

Other funds holding TTPH

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DRW Securities's TTPH Position: Q2 2014 in Review

DRW Securities sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2014, closing a stake of 950 shares — an estimated $207K sold.

DRW Securities first reported a position in TTPH in Q1 2014 and held it in 1 quarter. The position peaked at $207K in Q1 2014. 64 funds tracked by Wall St. Rank hold TTPH as of Q2 2014.

  • DRW Securities reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • DRW Securities sold 950 Tetraphase Pharmaceuticals, Inc. shares in Q2 2014, an estimated $207K.
  • DRW Securities first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • DRW Securities's Tetraphase Pharmaceuticals, Inc. position peaked at $207K in Q1 2014.
  • 64 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2014.

Based on DRW Securities's 13F filing for Q2 2014, filed 15 Aug 2014.